LEVETIRACETAM - Generic Drug Details

What are the generic sources for levetiracetam and what is the scope of freedom to operate?

Levetiracetam is the generic ingredient in six branded drugs marketed by Ucb Inc, Am Regent, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly Pharm, Hikma Farmaceutica, Hospira Inc, Jubilant Generics, Knack, Micro Labs, MSN, Mylan Labs Ltd, Prinston Inc, Sagent Pharms, Sun Pharm Inds Ltd, Xgen Pharms, B Braun Medical, Caplin, Gland, Hikma, Hq Spclt Pharma, Nexus, Actavis Mid Atlantic, Ajenat Pharms, Alembic, Amneal Pharms, Anda Repository, Apotex Inc, Aurobindo Pharma, Bionpharma, Chartwell Molecular, Hetero Labs Ltd Iii, Lupin Ltd, Pharm Assoc, Pharmobedient Cnsltg, Quagen, Strides Pharma, Taro, Tolmar, Tripoint, Actavis Elizabeth, Actavis Labs Fl Inc, Adaptis, Aiping Pharm Inc, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Hisun Pharm Hangzhou, Lotus Pharm Co Ltd, Overseas, Ph Health, Pharmadax, Rouses Point Pharms, Sandoz, Sciegen Pharms, Sun Pharm, Sun Pharm Industries, Teva Pharms, Torrent Pharms Ltd, Aprecia Pharms, Accord Hlthcare, Alkem Labs Ltd, China Resources, Fosun Pharma, Granules, Ingenus Pharms Llc, Invagen Pharms, Lupin, Mpp Pharma, Mylan, Novax, Orbion Pharms, Oxford Pharms, Rising, Senores Pharms, Torrent Pharms, Watson Labs Inc, Zhejiang Jingxin, and Zydus Pharms Usa Inc, and is included in one hundred and thirteen NDAs. There are ten patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Eighty-eight suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LEVETIRACETAM

International Patents:	92
US Patents:	10
Tradenames:	6
Applicants:	81
NDAs:	112
Finished Product Suppliers / Packagers:	87
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	249
Patent Applications:	7,146
Drug Prices:	Drug price trends for LEVETIRACETAM
Drug Sales Revenues:	Drug sales revenues for LEVETIRACETAM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVETIRACETAM
What excipients (inactive ingredients) are in LEVETIRACETAM?	LEVETIRACETAM excipients list
DailyMed Link:	LEVETIRACETAM at DailyMed

See drug prices for LEVETIRACETAM

See drug sales revenues for LEVETIRACETAM

Recent Clinical Trials for LEVETIRACETAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospices Civils de Lyon	PHASE3
Mansoura University	PHASE4
Beijing Tiantan Hospital	PHASE3

See all LEVETIRACETAM clinical trials

Generic filers with tentative approvals for LEVETIRACETAM

Applicant	Application No.	Strength	Dosage Form
		500MG	TABLET;ORAL
		1GM	TABLET;ORAL
		750MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LEVETIRACETAM

Physiological Effect

Decreased Central Nervous System Disorganized Electrical Activity

Anatomical Therapeutic Chemical (ATC) Classes for LEVETIRACETAM

N03AX	Other antiepileptics
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LEVETIRACETAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KEPPRA XR	Extended-release Tablets	levetiracetam	1000 mg	022285	2	2011-01-07
KEPPRA	Tablets	levetiracetam	1000 mg	021035	1	2007-01-24

US Patents and Regulatory Information for LEVETIRACETAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Senores Pharms	LEVETIRACETAM	levetiracetam	TABLET;ORAL	076920-001	Jan 15, 2009	AB	RX	No	No
Tripoint	ELEPSIA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204417-001	Dec 20, 2018		DISCN	Yes	No			Y
Hetero Labs Ltd Iii	LEVETIRACETAM	levetiracetam	TABLET;ORAL	090515-004	Oct 8, 2010	AB	RX	No	No
Sciegen Pharms	LEVETIRACETAM	levetiracetam	TABLET;ORAL	215069-004	May 27, 2022	AB	RX	No	No
Zydus Pharms Usa Inc	LEVETIRACETAM	levetiracetam	TABLET;ORAL	078918-002	Apr 29, 2009	AB	RX	No	No
Gland	LEVETIRACETAM IN SODIUM CHLORIDE	levetiracetam	INJECTABLE;INTRAVENOUS	206880-003	Oct 25, 2017	AP	RX	No	No

Expired US Patents for LEVETIRACETAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-001	Nov 30, 1999
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-002	Jul 31, 2015
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-002	Jul 31, 2015
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-001	Jul 31, 2015
Ucb Inc	KEPPRA	levetiracetam	SOLUTION;ORAL	021505-001	Jul 15, 2003
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-001	Jul 31, 2015

EU/EMA Drug Approvals for LEVETIRACETAM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma SA	Keppra	levetiracetam	EMEA/H/C/000277Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	no	no	no	2000-09-29
Pfizer Europe MA EEIG	Levetiracetam Hospira	levetiracetam	EMEA/H/C/002783Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.	Authorised	yes	no	no	2014-01-07
Accord Healthcare S.L.U.	Levetiracetam Accord	levetiracetam	EMEA/H/C/002290Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Pharmathen S.A.	Matever	levetiracetam	EMEA/H/C/002024Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Actavis Group PTC ehf	Levetiracetam Actavis	levetiracetam	EMEA/H/C/002355Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Actavis Group PTC ehf	Levetiracetam Actavis Group	levetiracetam	EMEA/H/C/002305Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis Group is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-12-04

International Patents for LEVETIRACETAM

Country	Patent Number	Title	Estimated Expiration
Australia	2014228990
Australia	2017202752
Canada	2906029
China	105188849
China	109908355	包含左乙拉西坦的快速分散剂型 (Rapid disperse dosage form containing levetiracetam)
European Patent Office	2968994	FORME PHARMACEUTIQUE À DISPERSION RAPIDE CONTENANT DU LÉVÉTIRACÉTAM (RAPID DISPERSE DOSAGE FORM CONTAINING LEVETIRACETAM)

Supplementary Protection Certificates for LEVETIRACETAM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0162036	C300028	Netherlands		PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
0162036	2000C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329

Levetiracetam Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

Last updated: September 22, 2026

Levetiracetam is a mature anti-seizure medicine with broad global use, extensive generic competition, and declining originator revenue. UCB’s Keppra franchise remains commercially significant because of high prescription volume, pediatric and hospital use, and multiple dosage forms, but price erosion has shifted value from the branded product to low-cost generic suppliers. Immediate-release levetiracetam has lost primary exclusivity in the United States, while extended-release and formulation-related protections have provided narrower, later-stage barriers.

What is the current market position of levetiracetam?

Levetiracetam is a broad-spectrum antiseizure medication marketed primarily as Keppra by UCB. It is approved for adjunctive treatment of partial-onset seizures, myoclonic seizures associated with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures. The product is available in tablets, oral solution, injection, and extended-release tablets.[1]

The commercial market has four defining characteristics:

1. High global prescription volume.
2. Extensive generic substitution.
3. Low average selling prices for immediate-release products.
4. Continued demand from hospitals, pediatric patients, and patients stabilized on established regimens.

Levetiracetam has remained widely prescribed because it has limited clinically meaningful drug-drug interactions, does not require routine therapeutic drug monitoring, and is available in intravenous and oral forms. Its main commercial weaknesses are generic price competition and the availability of other newer antiseizure drugs.

How does levetiracetam compare with competing antiseizure drugs?

Drug	Originator	Main competitive position	Patent and market status
Levetiracetam	UCB, Keppra	High-volume broad-spectrum therapy; strong hospital and pediatric use	Immediate-release generic; extended-release generic competition
Lacosamide	UCB, Vimpat	Partial-onset seizures; branded and generic competition	U.S. primary exclusivity ended; generics widely available
Brivaracetam	UCB, Briviact	SV2A mechanism with greater selectivity than levetiracetam	Later-life branded product with more remaining commercial value
Lamotrigine	GlaxoSmithKline, Lamictal	Broad use, including bipolar disorder	Long-generic market
Valproate	Multiple originators	Broad-spectrum efficacy and low cost	Generic; safety restrictions affect certain populations
Perampanel	Eisai, Fycompa	Adjunctive treatment for focal and generalized seizures	Branded product with narrower market
Cenobamate	SK Biopharmaceuticals, Xcopri	Drug-resistant focal epilepsy	Newer branded therapy with higher pricing and growth potential

Levetiracetam competes most directly with lacosamide, lamotrigine, valproate, brivaracetam, and other generic antiseizure medicines. Brivaracetam has been positioned as a differentiated successor within UCB’s SV2A portfolio, but levetiracetam retains the advantage of lower cost and longer clinical familiarity.

What is the financial trajectory of Keppra and levetiracetam?

Keppra revenue has followed the standard lifecycle of a small-molecule blockbuster: rapid adoption after launch, peak branded sales, patent-driven generic entry, and gradual decline in originator revenue.

UCB’s annual reporting shows a long-term reduction in Keppra sales after generic entry. Reported figures have varied by currency, geographic mix, and accounting period, but the direction is consistent.

Period	Commercial phase	Financial effect
1999-2007	U.S. branded expansion	Rapid prescription and revenue growth
2008-2010	U.S. immediate-release generic entry	Major price and share erosion
2011-2018	Mature generic market	Continued unit demand but lower branded revenue
2019-2022	Legacy product decline	Lower UCB sales; continued global cash generation
2023-2024	Mature post-exclusivity franchise	Ongoing decline, offset partly by hospital, injection, pediatric, and international demand

UCB has continued to report Keppra revenue in the hundreds of millions of euros annually, but the product is no longer the company’s primary growth engine. UCB’s newer products, including Bimzelx, Fintepla, Briviact, and Cimzia, have assumed a larger role in the company’s growth strategy.[2]

The economic value of levetiracetam is now concentrated in:

• Manufacturing scale.
• Institutional contracts.
• Supply reliability.
• Regional distribution.
• Injectable and oral-solution demand.
• Formulation-specific products.
• Brand retention among stable patients and prescribers.

For generic manufacturers, the product remains attractive because demand is large and manufacturing technology is comparatively established. Margins are lower than for protected specialty medicines, but volume supports participation by multiple suppliers.

When did levetiracetam lose U.S. market exclusivity?

U.S. immediate-release levetiracetam lost meaningful market exclusivity in the late 2000s. The original Keppra approval occurred in 1999, and generic levetiracetam products entered after the expiration or resolution of the principal immediate-release patent barriers.

The main timeline is:

Event	Date
Original U.S. Keppra approval	1999
Immediate-release patent protection	Expired before or around the initial generic-entry period
Generic levetiracetam tablet approvals and launches	2008 onward
Keppra XR approval	2008
Extended-release generic competition	Emerged after later formulation protections expired or were no longer commercially effective

The exact entry date differed by dosage form, manufacturer, regulatory pathway, and litigation outcome. Generic entry did not eliminate the market. It changed the market from branded monopoly pricing to multi-supplier purchasing and substantial substitution.

What patents protect levetiracetam and Keppra?

Levetiracetam’s patent estate has included composition, formulation, dosage-form, and manufacturing-related rights. The core active ingredient patent is no longer a practical barrier to U.S. generic competition.

Core composition patent

UCB’s foundational levetiracetam patent was U.S. Patent No. 4,943,639. The patent covered levetiracetam and related compounds and was filed before the modern 20-year patent-term regime. Its term expired before the current generic market matured.

Extended-release formulation patents

Keppra XR relied on later formulation and dosage-form protection. U.S. Patent No. 6,713,092 is associated with extended-release levetiracetam technology and was listed in connection with the extended-release product. The commercial importance of these patents declined as their terms ended and generic extended-release products entered the market.

Orange Book-listed rights for drug products can change through patent delistings, expiration, corrections, or product-specific updates. The FDA Orange Book remains the controlling public source for current listed patents and exclusivity entries.[3]

What formulations are protected by levetiracetam patents?

The principal commercial dosage forms have been:

• Immediate-release tablets.
• Oral solution.
• Intravenous injection.
• Extended-release tablets.
• Generic equivalents in multiple strengths.

Immediate-release tablets and oral solution have faced extensive generic competition. Intravenous levetiracetam has additional commercial value because hospitals require dependable injectable supply, although the active ingredient itself is not protected by meaningful composition-patent exclusivity.

Extended-release products have historically had stronger formulation protection than standard tablets because release profiles, matrix systems, coating technology, dissolution behavior, and dosing schedules can support separate patent claims. Those protections are narrower than composition patents and are vulnerable to design-around strategies.

What is the Orange Book status of Keppra?

Keppra’s Orange Book position is materially weaker than during its branded-exclusivity period. The FDA lists approved levetiracetam products and any associated patents or regulatory exclusivities in the Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[3]

For market analysis, the relevant distinctions are:

Product type	Orange Book and generic implications
Keppra immediate-release tablets	Generic competition established
Keppra oral solution	Generic competition established
Keppra injection	Generic competition established, with supply and contracting remaining important
Keppra XR	Formulation-specific generic review and historical patent barriers
Authorized or branded generic products	Limited ability to preserve premium pricing

Current commercial protection is therefore based more on brand, supply, formulation, and distribution than on enforceable exclusivity for the active ingredient.

Which companies challenged or competed against Keppra?

Generic competition has involved major and regional manufacturers, including Teva, Mylan, Sandoz, Sun Pharmaceutical, Lupin, Dr. Reddy’s Laboratories, and other approved suppliers. The specific competitors vary by dosage form, strength, country, and procurement channel.

The competitive structure has three layers:

U.S. retail generics

Retail pharmacies and pharmacy benefit managers have driven substitution toward low-cost levetiracetam tablets and oral solutions. Large generic suppliers compete primarily on price, availability, manufacturing capacity, and wholesaler relationships.

Hospital suppliers

Hospitals purchase injectable levetiracetam through group purchasing organizations, direct contracts, wholesalers, and shortage-sensitive procurement channels. Injectable supply interruptions can temporarily improve pricing or market share for suppliers with available inventory.

International suppliers

Outside the United States, levetiracetam is supplied by branded subsidiaries, national generic manufacturers, contract manufacturers, and distributors. Market structure differs substantially because patent terms, regulatory standards, reimbursement, and tender systems vary by country.

What Paragraph IV challenges and patent litigation affected levetiracetam?

The principal U.S. litigation risk occurred when generic applicants sought approval before the expiration of listed patents through Paragraph IV certifications under the Hatch-Waxman Act. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed.

Levetiracetam litigation has been more commercially important for extended-release products than for the mature immediate-release market. Disputes have generally focused on:

• Whether a generic release profile falls within formulation claims.
• Whether asserted claims are obvious.
• Whether the patent specification supports the claimed formulation.
• Whether the generic product infringes through its release mechanism.
• Whether patent listings properly cover the approved product.

The practical result has been staged market entry rather than a single uniform generic launch date. Immediate-release competition became entrenched earlier, while extended-release competition developed later and was more dependent on formulation patents and settlement or litigation outcomes.

Are there settlement agreements affecting levetiracetam generic entry?

Patent settlements may determine whether a generic launches before patent expiration, at the expiration date, or under a license. Publicly reported settlement terms are not always complete, and agreements may include confidential commercial provisions.

For levetiracetam, settlement economics are less important to the long-term market than the underlying loss of exclusivity. Once multiple generic manufacturers entered the immediate-release market, price competition became structural. A settlement affecting one applicant would not preserve durable monopoly economics if other applicants could enter later.

The key diligence point is to distinguish:

• First Paragraph IV filer economics.
• Authorized-generic arrangements.
• Formulation-specific settlements.
• Launch-at-risk exposure.
• Subsequent ANDA approvals after the first entrant.

What is the FDA regulatory status of levetiracetam?

Levetiracetam is an FDA-approved small-molecule antiseizure drug. The original Keppra product was approved in 1999, and the FDA later approved additional dosage forms, including an extended-release tablet and an intravenous formulation.[1]

The regulatory market has low scientific entry barriers relative to biologics. Generic applicants generally rely on an abbreviated new drug application demonstrating pharmaceutical equivalence and bioequivalence. The principal regulatory issues are:

• Dosage-form equivalence.
• Extended-release dissolution profiles.
• Labeling consistency.
• Injectable manufacturing quality.
• Stability and impurity controls.
• Facility inspection and supply continuity.

Biosimilar risk does not apply to levetiracetam because it is a chemically synthesized small molecule, not a biologic. The relevant competitive risk is generic substitution, not biosimilar interchangeability.

How strong is the levetiracetam patent estate?

The current patent estate is weak for the active ingredient and mature immediate-release products. It is stronger, but narrower, for proprietary release technologies and product-specific formulations.

Patent category	Current strength
Active ingredient	Weak; core protection expired
Immediate-release tablets	Weak; generic competition established
Oral solution	Weak to moderate; formulation and regulatory execution matter more than exclusivity
Intravenous injection	Weak from a composition standpoint; manufacturing and supply reliability remain relevant
Extended-release tablets	Historically moderate; narrower formulation claims and design-around risk
Manufacturing processes	Potentially useful but difficult to enforce as a broad market barrier
Brand and trade dress	Limited legal exclusivity; can support residual demand but not block substitution

For licensing or litigation purposes, a remaining formulation patent should be assessed claim by claim. Patent expiration alone does not determine practical risk. Claim scope, prosecution history, obviousness exposure, product design, and the number of generic applicants are more important.

What generic entry risks exist for levetiracetam?

The generic launch environment is mature, but several risks remain relevant to manufacturers and investors.

Price compression

Multiple approved suppliers can reduce prices rapidly, especially for immediate-release tablets. The product is vulnerable to tender-based purchasing and pharmacy benefit manager substitution.

Manufacturing concentration

Although levetiracetam synthesis is established, active pharmaceutical ingredient and finished-dose supply can be concentrated among a limited number of facilities. Regulatory actions, quality failures, geopolitical disruptions, or transportation problems can affect availability.

Injectable supply risk

Hospitals may shift purchasing toward suppliers with reliable injectable inventory. Shortages can produce temporary share changes, but they do not usually restore durable brand pricing.

Formulation litigation

Extended-release products can generate patent disputes because small differences in release kinetics may affect infringement and bioequivalence analyses.

Regulatory enforcement

FDA inspection findings, data-integrity concerns, manufacturing deviations, or import alerts can remove a supplier from the market and increase short-term pricing for remaining manufacturers.

What licensing deals affect levetiracetam?

UCB developed and commercialized Keppra through its own pharmaceutical operations and related regional commercial structures. The broader levetiracetam market includes licensing, distribution, contract manufacturing, and authorized-generic arrangements, but these transactions generally concern geographic commercialization or supply rather than a new therapeutic platform.

The most valuable commercial rights are now likely to involve:

• Regional distribution.
• Hospital injectable supply.
• Government tenders.
• Pediatric oral-solution channels.
• Authorized-generic commercialization.
• Contract manufacturing capacity.

Traditional discovery-stage licensing has limited strategic value because the active ingredient is mature and widely available. Deal value is more likely to reflect volume, geographic access, regulatory approvals, and manufacturing cost.

How does levetiracetam affect UCB’s revenue exposure?

Keppra remains a recurring revenue contributor but is a declining share of UCB’s strategic portfolio. UCB’s financial exposure has shifted toward products with stronger growth or differentiation, including Bimzelx in immunology and newer epilepsy products such as Fintepla and Briviact.[2]

The financial profile is therefore asymmetric:

• UCB faces continued revenue erosion from generic substitution.
• Generic manufacturers gain volume but face margin compression.
• Hospitals benefit from supplier competition but remain exposed to shortages.
• Investors should treat Keppra as a cash-generating legacy asset, not a growth asset.
• The franchise retains value through scale and clinical familiarity rather than patent-based pricing power.

What generic launch scenarios are most likely?

Immediate-release products

Generic levetiracetam tablets and oral solutions are already established. Further launches are likely to redistribute share rather than create a new market event. Price competition will remain intense.

Extended-release products

Extended-release generic launches can produce a more visible share shift because patients and payers may transition between branded and generic products over time. Patent litigation and product-specific regulatory review remain more relevant than for immediate-release tablets.

Injectable products

The principal risks are supply continuity and contracting. A supplier with reliable injectable capacity can gain share even without meaningful patent protection.

Branded retention

Some patients will remain on Keppra because of clinical stability, prescriber preference, formulary design, or patient concern about switching. That retention supports residual branded revenue but does not prevent long-term erosion.

What is the geographic coverage of levetiracetam?

Levetiracetam is marketed globally under Keppra and numerous generic names. The United States, Europe, Japan, China, and emerging markets have different patent, reimbursement, and procurement dynamics.

Europe is highly exposed to national reimbursement and tender systems. Emerging markets are more sensitive to affordability and local manufacturing. Japan and other regulated markets may impose distinct bioequivalence, labeling, and post-approval requirements. Global revenue analysis must therefore separate:

• Branded sales.
• Generic sales.
• Hospital products.
• Retail products.
• Tender markets.
• Private-pay markets.

Key Takeaways

• Levetiracetam is a mature, high-volume antiseizure medicine with extensive generic competition.
• UCB’s Keppra franchise lost meaningful U.S. immediate-release exclusivity in the late 2000s.
• The core composition patent is expired and does not prevent generic entry.
• Extended-release formulations historically had stronger protection, but those barriers are narrower and have eroded.
• The FDA regulatory pathway is established, and biosimilar risk is irrelevant because levetiracetam is a small molecule.
• UCB’s Keppra revenue has declined over time as generic substitution expanded.
• Current value is concentrated in manufacturing scale, injectable supply, oral-solution demand, international distribution, and residual brand use.
• Generic manufacturers face price compression, formulation litigation, quality enforcement, and supply-chain risks.
• Keppra is a legacy cash-generating product for UCB rather than a primary growth driver.

FAQs

Is levetiracetam still profitable after generic entry?

Yes. Profitability remains possible because prescription volume is high and manufacturing processes are established. Profit per unit is substantially lower than during branded exclusivity.

Does levetiracetam require a biosimilar development program?

No. Levetiracetam is a chemically synthesized small molecule. Generic applicants typically pursue abbreviated new drug applications rather than biosimilar applications.

Is Keppra XR protected by separate patents from regular Keppra?

Yes. Extended-release products rely on formulation and release-profile protections that are distinct from the original active-ingredient patent. Those patents have narrower scope and greater design-around exposure.

Can a generic manufacturer launch levetiracetam before all patents expire?

Potentially. A manufacturer may file a Paragraph IV certification and challenge listed patents. Entry then depends on litigation, settlement, patent validity, infringement findings, regulatory approval, and any applicable exclusivity.

Is levetiracetam a growth opportunity for pharmaceutical investors?

The active ingredient is generally a mature, low-growth opportunity. Investment upside is more likely to come from manufacturing efficiency, supply reliability, injectable capacity, regional market access, or differentiated products such as newer antiseizure medicines.

References

1. U.S. Food and Drug Administration. (2024). Keppra (levetiracetam) prescribing information. FDA.
2. UCB. (2024). Annual report 2023. UCB S.A.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Patent and Trademark Office. (1988). U.S. Patent No. 4,943,639: Anticonvulsant compounds.
5. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,713,092: Extended-release formulation of levetiracetam.